A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene
about
A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Surgically Unresectable Urothelial Cancer With Selected FGFR Gene
description
clinical trial
@en
klinisch onderzoek
@nl
name
A Study to Evaluate Safety, Ef ...... Cancer With Selected FGFR Gene
@en
type
label
A Study to Evaluate Safety, Ef ...... Cancer With Selected FGFR Gene
@en
prefLabel
A Study to Evaluate Safety, Ef ...... Cancer With Selected FGFR Gene
@en
P17
P6153
P1476
A Phase 1b-2 Study to Evaluate ...... Selected FGFR Gene Alterations
@en
P3098
NCT03473743
P580
2018-04-05T00:00:00Z
P582
2019-10-21T00:00:00Z